MRK vs MSFT: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Microsoft Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
VS
Microsoft Corporation · Technology
$497.12
+41.3% upside to fair value
High Conviction
Grade A
High Quality
QuantHub Verdict
MSFT has more upside to fair value
(+41.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
MSFT |
| Current Price |
$147.17 |
$497.12 |
| Fair Value Estimate |
$141.07 |
$702.35 |
| Upside to Fair Value |
-4.1%
|
+41.3%
|
| Market Cap |
$363.5B |
$3,691.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
29.6x
|
18.3x
|
| Price / Sales |
5.5x
|
11.1x
|
| Price / FCF |
22.6x
|
55.1x
|
| Revenue Growth YoY |
+5.1%
|
+17.7%
|
| Gross Margin |
75.4%
|
67.9%
|
| Operating Margin |
16.7%
|
46.8%
|
| Return on Equity |
6.6%
|
33.2%
|
| Dividend Yield |
2.31% |
0.73% |
| FCF Yield |
4.42%
|
1.81%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Microsoft is a global infrastructure-software platform spanning Azure, Microsoft 365, security, Dynamics, Windows, GitHub and AI copilots, with high business quality supported by enterprise distribution, explicitly cited switching costs, a $678 billion commercial RPO balance, 67.9% TTM gross margin, 46.8% TTM operating margin, 40.3% TTM net margin and 33.2% ROE. Revenue grew 17.7% and earnings gr…
Accumulation Zones
| Metric |
MRK |
MSFT |
| Zone Low |
$105.80 |
$526.76 |
| Zone High |
$119.91 |
$597.00 |
| In Buy Zone? |
No
|
Yes
|